How has Aclaris Therapeutics's contract liabilities, non-current changed year-over-year?

Aclaris Therapeutics's contract liabilities, non-current decreased by 20.4% year-over-year, from $19.21M to $15.29M.

Aclaris Therapeutics ACRS Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Kymera TherapeuticsKYMR

——

CytomX TherapeuticsCTMX

——

Arcus BiosciencesRCUS

——

Alumis Inc.ALMS

——

Janux TherapeuticsJANX

——

Kura OncologyKURA

——

Other financials

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

See full

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's contract liabilities, non-current?: Aclaris Therapeutics (ACRS) reported contract liabilities, non-current of $15.29M in Q1 2026.
How has Aclaris Therapeutics's contract liabilities, non-current changed year-over-year?: Aclaris Therapeutics's contract liabilities, non-current decreased by 20.4% year-over-year, from $19.21M to $15.29M.